Sponsor Deadline
Posted: 4/18/2022

ADOPTION OF BIOSIMILARS IN ONCOLOGY

The National Comprehensive Cancer Network® (NCCN) and Pfizer Global Medical Grants (Pfizer) are collaborating to offer a new grant opportunity seeking proposals in support of the adoption of biosimilars in oncology.

The intent of this RFP is to encourage NCCN Member Institutions and non-NCCN Member Institutions to submit proposals describing concepts and ideas that develop and validate enduring approaches that improve the safe and efficient adoption of biosimilars in oncology. Proposals that directly measure increases in biosimilar use or improve safety, value and efficiency in oncology practices will be prioritized. The sustainability and broad applicability of the approach will be key factors in evaluating funded projects.

The intent of the RFP is to encourage organizations to submit letters of intent (LOIs) describing concepts and ideas that improve the safe and efficient adoption or utilization of biosimilars in oncology. Emphasis is placed on adding value to the oncology care model through safe and effective use of biosimilars as well as the sustainability and broad applicability across university and community-based practices.

The creation of a sustainable and competitive marketplace for originator biologics and biosimilars has the potential to improve patient access to biologics, increase treatment options, and generate savings and efficiencies for health care systems.

Deadline for LOI: Sep. 9, 2020

Areas of Interest

NCCN and Pfizer encourage proposals studying any of the following (not inclusive):

1. Quality of care and best practices around the appropriate use of biosimilars

2. Quality of care and best practices around the perceptions of biosimilars

3. Quality/Process improvement projects that impact efficiency and resource utilization

4. Educational tools for providers, nurses, pharmacists, administrative units

5. Pharmacy and Therapeutic Committee processes

6. Pharmacy practices that improve the safety or use of biosimilars

7. Electronic medical records and integration of biosimilars

8. Tools impacting prescribing behaviors

9. Clinical pathway and consensus guidelines development

10. Challenges related to payer mandates/insurance issues

11. Optimization and integration of processes

12. Value/Quality/Cost for patients, clinicians and institutions

Eligibility Requirements

This RFP is open to investigators from all US institutions and organizations. Collaboration between institutions is strongly encouraged in order to foster the interactive sharing of knowledge and expertise, and to utilize the combined strengths of members.

• Restricted to US institutions • Academic and Community Centers (Principal Investigators {PIs} from Academic Centers are encouraged to include a co-investigator from the community) • Patient Advocacy Groups • Open to any type of care delivery system with the exception small, physician-owned group practices • Health care professional organizations and other organizations with a mission related to health care improvement

Amount Description

Individual projects requesting up to $250,000 (direct and indirect costs) will be considered; smaller, lower-cost projects are strongly encouraged.